News and presentations

News and presentations

Press Releases 


04/24/2019

Cinclus Pharma secures financing for preparation of Phase 2 study of X842

 

04/16/2018

First clinical study successfully completed with X842, an innovative promising treatment for severe erosive GERD

 


Scientific publications

 

Phase 1 results presented at DDW, Washington, US, June 2018

The new P-CAB X482 was safe, tolerable and provided 24h intragastric control, after single oral doses in healthy volunteers

 

Crawley & Schmitt, JCOM, November 2000

How satisfied are chronic heartburn sufferers with their prescription medications? Results of the patient unmet needs study.

 

 

 

 

 


Cinclus Pharma AB

Trädgårdsgatan 54

431 35 Mölndal

SWEDEN

info@cincluspharma.com

Kjell Andersson, CEO

+46 733 337 906


Peter Unge, CMO

+46 705 763 780

Copyright © All Rights Reserved